Dyskinesias
Abnormal involuntary movements which primarily affect the extremities, trunk, or jaw that occur as a manifestation of an underlying disease process. Conditions which feature recurrent or persistent episodes of dyskinesia as a primary manifestation of disease may be referred to as dyskinesia syndromes (see MOVEMENT DISORDERS). Dyskinesias are also a relatively common manifestation of BASAL GANGLIA DISEASES.
Subtype terms (13)
More specific conditions that are subtypes of Dyskinesias in the MeSH hierarchy.
- Ataxia
10 drugs (9 approved, 1 experimental)
- Athetosis
1 drug approved
- Catalepsy
- Chorea
12 drugs (10 approved, 2 experimental)
- Dyskinesia, Drug-Induced
13 drugs (8 approved, 5 experimental)
- Dystonia
21 drugs (14 approved, 7 experimental)
- Hyperkinesis
3 drugs (2 approved, 1 experimental)
- Hypokinesia
3 drugs (1 approved, 2 experimental)
- Myoclonus
13 drugs (12 approved, 1 experimental)
- Psychomotor Agitation
36 drugs (31 approved, 5 experimental)
- Synkinesis
4 drugs approved
- Tics
3 drugs approved
- Tremor
17 drugs (13 approved, 4 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (4)
Phase 3 trials (6)
Phase 2 trials (11)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (20)
- Allergan
- Neurocrine Biosciences
- Michael J. Fox Foundation for Parkinson's Research
- Hoosier Cancer Research Network
- Stanley Medical Research Institute
- Taoyuan General Hospital
- University of California, San Francisco
- University of Cincinnati
- Uppsala University
- Taipei Veteran General hospital
- Rush University
- YuLi Hospital
- Stellenbosch University
- Technical University of Dresden
- Department of Veteran Affairs
- Rowan University
- Swedish Parkinson's Disease Foundation
- Swedish Society for Medical Research
- Johnson and Johnson
- Government of Taiwan
Organization Involved with Phase 3 Indications (20)
- Adamas Pharmaceuticals, Inc.
- AbbVie
- Auspex Pharmaceuticals
- Merck Serono
- Zambon
- GlaxoSmithKline
- Teva
- Emory University
- Herzog Hospital
- Yale University
- Peking University
- Sha'ar Menashe Mental Health Center
- Osmotica Pharmaceutical
- Technion University
- Mitsubishi Tanabe
- University of Paris
- Ben Gurion University
- Atlanta Clinical and Translational Science Institute
- University of Picardie Jules Verne
- IQVIA
Organization Involved with Phase 2 Indications (46)
- Abbott
- Eisai
- Medicure
- Vertex
- Merck
- Avanir
- Novartis
- Bukwang Pharmaceutical
- Neurim Pharmaceuticals Ltd.
- Parion Sciences
- Synchroneuron Inc.
- VistaGen Therapeutics, Inc.
- Amarantus BioScience Holdings, Inc.
- Neuraltus Pharmaceuticals, Inc.
- Prexton Therapeutics
- National Institutes of Health (NIH)
- National Center for Research Resources (NCRR)
- National Institute of General Medical Sciences (NIGMS)
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Arizona
- CAMC Health System
- University of London
- Loma Linda University
- Queen's University, Belfast
- University of Ioannina
- University of Kentucky
- University of Plymouth
- University of Rostock
- University of Toronto
- West Virginia University
- +16 more
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (12)
- Merck KGaA
- Huai'an First People's Hospital
- Nanjing University of Traditional Chinese Medicine
- Qingdao University
- Shanghai University of Traditional Chinese Medicine
- Xuzhou Medical University
- Wenzhou Medical University
- Jiao Tong University
- University of North Carolina at Chapel Hill
- Foundation of Hope, North Carolina
- Xin Hua Hospital of Zhejiang Province
- Jiangsu Province Hospital